Review of Global Incidence and Prevalence of Systemic Sclerosis
Study authors conducted a systematic review and meta-analysis on the incidence and prevalence of systemic sclerosis.
Study authors conducted a systematic review and meta-analysis on the incidence and prevalence of systemic sclerosis.
Researchers assessed the safety and efficacy of B-cell depletion for systemic sclerosis-associated pulmonary arterial hypertension.
The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD.
The researchers conducted an extensive pain assessment of patients with systemic sclerosis, examining pain chronification and its association with disease manifestations.
A team of investigators sought to determine the prevalence of proton pump inhibitor-partial response gastroesophageal reflux disease in patients with systemic sclerosis.
The FDA has granted Orphan Drug designation to TMB-003 (Timber Pharmaceuticals) for the treatment of systemic sclerosis.
Researchers evaluated obstetric complications in women with a systemic sclerosis diagnosis vs the general obstetric population.
The performance of 5 core set measure in ACR-CRISS in recent trials was explored, and their ability to discern the active medication group from placebo in patients with diffuse cutaneous systemic sclerosis (dcSSc), was assessed.
Close monitoring of patients with systemic sclerosis-associated interstitial lung disease and awareness of the variable course of progression is highly important in considering when to initiate treatment.
In this open-label extension study, researchers reported on the safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis.